UBS maintains Buy rating on 3SBio with HK$26.40 price target

Oct 31, 2026 01:29 (12h ago)

UBS maintained a Buy rating on 3SBio on October 28 and set a HK$26.40 price target.
3SBio closed at HK$13.69, while Strong Buy consensus indicated a HK$28.87 target and 110.90% upside.
CMB International Securities maintained Buy with a HK$34.78 target on October 29, while the older record identified Sino Biopharmaceutical and Simcere instead.

UBS maintained a Buy rating on 3SBio in an October 28 report and set a HK$26.40 price target; the shares closed at HK$13.69. Analyst consensus rated the stock Strong Buy with a HK$28.87 target, implying 110.90% upside. CMB International Securities maintained Buy on October 29 with a HK$34.78 target. The older record instead identified Sino Biopharmaceutical and Simcere Pharmaceutical Group, reporting separate targets, share prices and Simcere financial results, so those figures are retained as a company-identity discrepancy rather than combined with 3SBio.